Nurix Therapeutics (NRIX) Other Working Capital Changes (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Other Working Capital Changes for 8 consecutive years, with $900000.0 the latest figure, recorded in Q2 2026.

• In Q2 2026, Other Working Capital Changes rose 164.29% year-over-year to $900000.0; the TTM figure through May 2026 stood at -$34.3 million (down 43.0% YoY), while the FY2025 annual figure was -$37.0 million, down 29.53% from the prior year.
• Other Working Capital Changes climbed to $900000.0 in Q2 2026 per NRIX's latest filing, from -$1.3 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $6.3 million in Q1 2025 and bottomed at -$3.3 million in Q2 2025.
• Historically, Other Working Capital Changes has averaged $227388.9 across 5 years, with a median of $209000.0 in 2022.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes jumped 210.65% — and 2024, when it sank 900.3%.
• Nurix Therapeutics' Other Working Capital Changes stood at $17.5 million in 2022, then plunged by 107.6% to -$1.3 million in 2023, then tumbled by 900.3% to -$13.3 million in 2024, then tumbled by 145.93% to -$32.7 million in 2025, then soared by 102.75% to $900000.0 in 2026.
• Business Quant data shows NRIX's Other Working Capital Changes at $900000.0 in Q2 2026, -$1.3 million in Q1 2026, and -$32.7 million in Q4 2025.